You are viewing a preview of...
A Rapid, High Content, Reagent Sparing, Fluorescent Plasmonic Assay Platform for Multiplexed Serum Antibody Detection in Lyme Disease and COVID-19
A protein microarray, in the form of a compact biochip, that can be analyzed with high sensitivity using GC-FP technology
Background
Some infectious diseases are easy to diagnose, but others are much more difficult. One example is Lyme disease (B. burgdorferi), which is caused by a slow-growing organism that takes many weeks to detect. Current testing is sub-optimal and confusing due to a high false negative rate; patients may be quite ill but appear normal on testing, and physicians may elect not to treat with multiple weeks of antibiotics. A lot rides on accurate, timely diagnosis and treatment; untreated Lyme disease can cause severe neurologic and cardiac issues. Another example is COVID-19, where PCR testing has proven to be problematic due to shortages of reagents, long wait times for results, and complicated findings of both false positives and false negatives;
Log in or create a free account to continue reading